Related Experiment Video
Updated: May 17, 2026
08:31
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform
Francis A Galaway1, Peter G Stockley
1Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.
Molecular Pharmaceutics
|November 1, 2012
Summary
This study demonstrates targeted virus-like particles (VLPs) for siRNA delivery, showing efficient cellular uptake and therapeutic effects. These engineered VLPs offer a promising platform for targeted drug delivery systems.
Area of Science:
- Biotechnology
- Nanotechnology
- Molecular Biology
Background:
- Virus-like particles (VLPs) offer a versatile platform for drug delivery.
- Targeted delivery systems are crucial for enhancing therapeutic efficacy and reducing side effects.
- RNA interference (RNAi) therapeutics require efficient and safe delivery vehicles.
Purpose of the Study:
- To develop and characterize targeted virus-like particles (VLPs) for siRNA delivery.
- To assess the efficiency of VLP reassembly and large-scale production.
- To evaluate the cellular uptake, nuclease protection, and therapeutic efficacy of targeted VLPs.
Main Methods:
- Reassembly of MS2 bacteriophage coat protein with siRNA and a capsid assembly signal.
- Covalent attachment of human transferrin for targeted delivery to HeLa cells.
- Purification of targeted VLPs and assessment of their cellular entry via receptor-mediated endocytosis.
- Evaluation of siRNA-mediated gene silencing effects at low nanomolar concentrations.
Main Results:
- Successfully engineered targeted VLPs capable of protecting siRNA cargo from nucleases.
- Demonstrated efficient cellular uptake of targeted VLPs via receptor-mediated endocytosis.
- Achieved significant siRNA effects at low nanomolar concentrations, comparable or superior to lipid-based delivery.
- Showcased improved siRNA pathway accessibility compared to lipid-encapsulated delivery.
Conclusions:
- Targeted VLPs represent a viable and effective system for siRNA delivery.
- The MS2 VLP system exhibits key features for an efficient targeted drug delivery platform.
- Fluorescence assays facilitate the analysis of VLP formulations and dosing for future optimization.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:16Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...